<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Lilly&#8217;s ImClone Cuts Nearly Half Its Sales Force</title>
	<atom:link href="http://www.pharmalot.com/2008/12/lillys-imclone-cuts-nearly-half-its-sale/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/12/lillys-imclone-cuts-nearly-half-its-sale/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 19:44:56 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: The Caped Crusader</title>
		<link>http://www.pharmalot.com/2008/12/lillys-imclone-cuts-nearly-half-its-sale/#comment-384047</link>
		<dc:creator>The Caped Crusader</dc:creator>
		<pubDate>Mon, 08 Dec 2008 21:02:40 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=18353#comment-384047</guid>
		<description>Yowza! Talk about a slash of a sales forcem. This is just the beginning of what happens with consolidation in pharma. So, with lower marketing will they lower the price for Erbitux which seems to be overpriced for what it delivers to say the very least!?  I won't wait up for that to happen, will you?</description>
		<content:encoded><![CDATA[<p>Yowza! Talk about a slash of a sales forcem. This is just the beginning of what happens with consolidation in pharma. So, with lower marketing will they lower the price for Erbitux which seems to be overpriced for what it delivers to say the very least!?  I won&#8217;t wait up for that to happen, will you?</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.148 seconds -->

